Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review)
- Authors:
- Dai Shimizu
- Yoshikuni Inokawa
- Fuminori Sonohara
- Kenichi Inaoka
- Shuji Nomoto
-
Affiliations: Department of Surgery, Aichi Gakuin University School of Dentistry, Chikusa-ku, Nagoya 464-8651, Japan - Published online on: March 31, 2017 https://doi.org/10.3892/or.2017.5541
- Pages: 2527-2542
This article is mentioned in:
Abstract
|
Grunstein M and Hogness DS: Colony hybridization: A method for the isolation of cloned DNAs that contain a specific gene. Proc Natl Acad Sci USA. 72:3961–3965. 1975. View Article : Google Scholar : PubMed/NCBI | |
|
Taura K, Ikai I, Hatano E, Fujii H, Uyama N and Shimahara Y: Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: An analysis of 610 patients over 16 years old. Ann Surg. 244:265–273. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y and Hino O: Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 29:1446–1452. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF, Chen PJ and Lin CH: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 119:431–440. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ochiai T, Urata Y, Yamano T, Yamagishi H and Ashihara T: Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. Hepatology. 31:615–621. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nomoto S, Yamashita K, Koshikawa K, Nakao A and Sidransky D: Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res. 8:481–487. 2002.PubMed/NCBI | |
|
Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H and Nakao A: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, Jin GZ, Cong WM and Wu MC: Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: A new strategy for hepatic surgery. J Am Coll Surg. 217:1054–1062. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ng IO, Guan XY, Poon RT, Fan ST and Lee JM: Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol. 199:345–353. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nomoto S, Hishida M, Inokawa Y, Sugimoto H and Kodera Y: Management of hepatocellular carcinoma should consider both tumor factors and background liver factors. Hepatobiliary Surg Nutr. 3:82–85. 2014.PubMed/NCBI | |
|
Xie B, Zen Q, Wang X, He X, Xie Y, Zhang Z and Li H: ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling. Int J Oncol. 46:2057–2066. 2015.PubMed/NCBI | |
|
Liu S, Zhang W, Liu K, Ji B and Wang G: Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep. 11:597–602. 2015.PubMed/NCBI | |
|
Gao L, Ge C, Fang T, Zhao F, Chen T, Yao M, Li J and Li H: ANGPTL2 promotes tumor metastasis in hepatocellular carcinoma. J Gastroenterol Hepatol. 30:396–404. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HX, Jiang SS, Zhang XF, Zhou ZQ, Pan QZ, Chen CL, Zhao JJ, Tang Y, Xia JC and Weng DS: Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget. 6:34800–34817. 2015.PubMed/NCBI | |
|
Cheng Q, Yuan F, Lu F, Zhang B, Chen T, Chen X, Cheng Y, Li N, Ma L and Tong T: CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Oncotarget. 6:4733–4744. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, Liu J, Yu S and He S: Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res. 35:822016. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan J, Zheng H, Rong X, Rong X, Zhang J, Fang W, Zhao P and Luo R: Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer. 15:172016. View Article : Google Scholar : PubMed/NCBI | |
|
Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu ZJ and Zhang ZY: Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma. Mol Med Rep. 11:1318–1323. 2015.PubMed/NCBI | |
|
Liu S, Long G, Wei H, Shi L, Yang Z, Liu D, Hu G and Qiu H: DJ-1 knockdown inhibits growth and xenograft-induced tumor generation of human hepatocellular carcinoma cells. Oncol Rep. 33:201–206. 2015.PubMed/NCBI | |
|
Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y and Huang J: Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget. 6:24132–24147. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CH, Lin YW, Chen YC, Liao CC, Jou YS, Hsu MT and Chen CF: FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma. Oncotarget. 7:49498–49508. 2016.PubMed/NCBI | |
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR, Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016. View Article : Google Scholar : PubMed/NCBI | |
|
Gao K, Xu C, Jin X, Wumaier R, Ma J, Peng J, Wang Y, Tang Y, Yu L and Zhang P: HDGF-related protein-2 (HRP-2) acts as an oncogene to promote cell growth in hepatocellular carcinoma. Biochem Biophys Res Commun. 458:849–855. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Yang XH, Fang SJ, Qin CF, Sun RL, Liu ZY, Jiang BY, Wu X and Li G: HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2. Oncol Rep. 33:990–996. 2015.PubMed/NCBI | |
|
Lv X, Li L, Lv L, Qu X, Jin S, Li K, Deng X, Cheng L, He H and Dong L: HOXD9 promotes epithelial-mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1332015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Tao X, Jin G, Jin H, Wang N, Hu F, Luo Q, Shu H, Zhao F, Yao M, et al: A targetable molecular chaperone Hsp27 confers aggressiveness in hepatocellular carcinoma. Theranostics. 6:558–570. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, et al: JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells. Oncotarget. 6:12723–12739. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Han S, Peng R, Jiao C, Wang X, Yang X, Yang R and Li X: Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. J Exp Clin Cancer Res. 35:372016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H, Zhang Y, You H, Tao X, Wang C, Jin G, Wang N, Ruan H, Gu D, Huo X, et al: Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep. 5:104662015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CH, Li M, Liu LL, Zhou RY, Fu J, Zhang CZ and Yun JP: LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget. 6:42118–42129. 2015.PubMed/NCBI | |
|
Yao Y, Dou C, Lu Z, Zheng X and Liu Q: MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem. 35:983–996. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G, et al: Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 9:1201–1206. 2015.PubMed/NCBI | |
|
Takami H, Kanda M, Oya H, Hibino S, Sugimoto H, Suenaga M, Yamada S, Nishikawa Y, Asai M, Fujii T, et al: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le Y, Zhang YF, Wei W, Guo RP and Shi M: MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology. 63:1227–1239. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, et al: NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett. 11:1847–1854. 2016.PubMed/NCBI | |
|
Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, Ng IO and Lo RC: PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget. 6:10880–10892. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z, Wu Y, Wang W, Wu J, Tao S, Yang X, et al: PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation. Oncogene. 34:5524–5535. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wong CM, Wei L, Law CT, Ho DW, Tsang FH, Au SL, Sze KM, Lee JM, Wong CC and Ng IO: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 63:474–487. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang T, Song B, Zhang J, Yang GS, Zhang H, Yu WF, Wu MC, Lu JH and Shen F: STK33 promotes hepatocellular carcinoma through binding to c-Myc. Gut. 65:124–133. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W, et al: Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J Cell Biochem. 116:2465–2475. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Liao W, Yuan Q, Ou Y and Huang J: TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget. 6:34309–34320. 2015.PubMed/NCBI | |
|
Zhang XF, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Wang DD, Jiang SS, et al: Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Mol Carcinog. 55:64–76. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, et al: Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 6:40920–40933. 2015.PubMed/NCBI | |
|
Chai JY, Modak C, Mouazzen W, Narvaez R and Pham J: Epithelial or mesenchymal: Where to draw the line? Biosci Trends. 4:130–142. 2010.PubMed/NCBI | |
|
Lu Q: δ-Catenin dysregulation in cancer: Interactions with E-cadherin and beyond. J Pathol. 222:119–123. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schackmann RC, Tenhagen M, van de Ven RA and Derksen PW: p120-catenin in cancer - mechanisms, models and opportunities for intervention. J Cell Sci. 126:3515–3525. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Liu YL, Chen GX, Cui B, Wang JS, Shi YL, Li LP and Guo XB: Heme oxygenase-1 promotes Caco-2 cell proliferation and migration by targeting CTNND1. Chin Med J. 126:3057–3063. 2013.PubMed/NCBI | |
|
Li T, Lai Q, Wang S, Cai J, Xiao Z, Deng D, He L, Jiao H, Ye Y, Liang L, et al: MicroRNA-224 sustains Wnt/β-catenin signaling and promotes aggressive phenotype of colorectal cancer. J Exp Clin Cancer Res. 35:212016. View Article : Google Scholar : PubMed/NCBI | |
|
Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J and Sanchez-Cespedes M: Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer. J Pathol. 222:89–98. 2010.PubMed/NCBI | |
|
Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, et al: Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 17:1317–1330. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ, Chang DK, et al: Australian Pancreatic Cancer Genome Initiative: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 109:5934–5941. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xing AY, Wang YW, Su ZX, Shi DB, Wang B and Gao P: Catenin-δ1, negatively regulated by miR-145, promotes tumour aggressiveness in gastric cancer. J Pathol. 236:53–64. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, Blanchard H and Ralph SJ: Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment. Cancer Metastasis Rev. 31:763–778. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI | |
|
Broder C and Becker-Pauly C: The metalloproteases meprin α and meprin β: Unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem J. 450:253–264. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lottaz D, Maurer CA, Hahn D, Büchler MW and Sterchi EE: Nonpolarized secretion of human meprin alpha in colorectal cancer generates an increased proteolytic potential in the stroma. Cancer Res. 59:1127–1133. 1999.PubMed/NCBI | |
|
Mujica AO, Brauksiepe B, Saaler-Reinhardt S, Reuss S and Schmidt ER: Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. FEBS J. 272:4884–4898. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et al: Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 209:697–711. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 137:821–834. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jelluma N, Brenkman AB, van den Broek NJ, Cruijsen CW, van Osch MH, Lens SM, Medema RH and Kops GJ: Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell. 132:233–246. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Shi R, He C, Cheng C, Song B, Cui H, Zhang Y, Zhao Z, Bi Y, Yang X, et al: Oncogenic B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. Cancer Lett. 337:125–132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, et al: A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 67:10148–10158. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, et al: TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One. 8:e637122013. View Article : Google Scholar : PubMed/NCBI | |
|
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 3:e16512008. View Article : Google Scholar : PubMed/NCBI | |
|
Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, et al: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 92:1805–1811. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gu D, Jin H, Jin G, Wang C, Wang N, Hu F, Luo Q, Chu W, Yao M and Qin W: The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity. Cancer Lett. 379:107–116. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang CF, Wen LZ, Yin C, Xu WP, Shi B, Zhang X and Xie WF: Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4α on hepatocellular carcinoma. Oncotarget. 7:27408–27421. 2016.PubMed/NCBI | |
|
Kanda M, Sugimoto H, Nomoto S, Oya H, Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S, et al: B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol. 46:641–648. 2015.PubMed/NCBI | |
|
Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, et al: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 44:44–52. 2014.PubMed/NCBI | |
|
Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, et al: Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res. 76:3265–3276. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F, Tian H, Chen T, Yao M and Li J: The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells. Oncotarget. 7:43534–43545. 2016.PubMed/NCBI | |
|
Zhang Y, Liu Y, Duan J, Yan H, Zhang J, Zhang H, Fan Q, Luo F, Yan G, Qiao K, et al: Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21Waf/Cip1 stabilization by activating the ERK1/2-MAPK pathway. Hepatology. 63:880–897. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu BH, Chen H, Cai CM, Fang JZ, Wu CC, Huang LY, Wang L and Han ZG: Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686. Oncotarget. 7:6847–6863. 2016.PubMed/NCBI | |
|
Tanaka Y, Kanda M, Sugimoto H, Shimizu D, Sueoka S, Takami H, Ezaka K, Hashimoto R, Okamura Y, Iwata N, et al: Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. Int J Oncol. 46:2546–2554. 2015.PubMed/NCBI | |
|
Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P and Sun B: The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog. 55:209–219. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li A, Yan Q, Zhao X, Zhong J, Yang H, Feng Z, Du Y, Wang Y, Wang Z, Wang H, et al: Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma. Oncotarget. 7:524–537. 2016.PubMed/NCBI | |
|
Ding X, Cheng X, Gong M, Chen X, Yin F and Lai K: Hypermethylation and expression silencing of PDCD4 gene in hepatocellular carcinoma: A consort study. Medicine. 95:e27292016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda M, Sugimoto H, Nomoto S, Oya H, Shimizu D, Takami H, Hashimoto R, Sonohara F, Okamura Y, Yamada S, et al: Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. Int J Oncol. 45:2005–2012. 2014.PubMed/NCBI | |
|
Richter AM, Walesch SK, Würl P, Taubert H and Dammann RH: The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer. Oncogenesis. 1:e182012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu XR, Cai CX, Luo LM, Zheng WL, Shi R, Zeng J, Xu YQ, Wei M and Ma WL: Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma. Cancer Cell Int. 16:152016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhou J, Zhou N, Zhu J, Feng Y and Miao X: SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 35:1152016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Lv L, Ouyang X, Zhang S, Fang J, Cai L and Li D: Association of TIP30 expression and prognosis of hepatocellular carcinoma in patients with HBV infection. Cancer Med. 5:2180–2189. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen CL, Pan QZ, Wu YY, Zhao JJ, Jiang SS, Chao J, Zhang XF, Zhang HX, Zhou ZQ, et al: Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget. 7:6323–6334. 2016.PubMed/NCBI | |
|
Shimizu D, Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Suenaga M, Inokawa Y, Hishida M, Takano N, et al: Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep. 31:1305–1313. 2014.PubMed/NCBI | |
|
Wu D, Liu G, Liu Y, Saiyin H, Wang C, Wei Z, Zen W, Liu D, Chen Q, Zhao Z, et al: Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1-mediated yes-associated protein inactivation. Hepatology. 64:1148–1162. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature. 439:811–816. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Huang Q and Li Y, Song Y and Li Y: JMJD5 is a potential oncogene for colon carcinogenesis. Int J Clin Exp Pathol. 8:6482–6489. 2015.PubMed/NCBI | |
|
Zhao Z, Sun C, Li F, Han J, Li X and Song Z: Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer. Int J Clin Exp Pathol. 8:10325–10334. 2015.PubMed/NCBI | |
|
Huang X, Zhang S, Qi H, Wang Z, Chen HW, Shao J and Shen J: JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation. Biochim Biophys Acta. 1853:2286–2295. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Soussi-Yanicostas N, de Castro F, Julliard AK, Perfettini I, Chédotal A and Petit C: Anosmin-1, defective in the X-linked form of Kallmann syndrome, promotes axonal branch formation from olfactory bulb output neurons. Cell. 109:217–228. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, Vannelli GB, Turnbull J and Bouloux PM: Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J Neurosci. 24:10384–10392. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jian B, Nagineni CN, Meleth S, Grizzle W, Bland K, Chaudry I and Raju R: Anosmin-1 involved in neuronal cell migration is hypoxia inducible and cancer regulated. Cell Cycle. 8:3770–3776. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Choy CT, Kim H, Lee JY, Williams DM, Palethorpe D, Fellows G, Wright AJ, Laing K, Bridges LR, Howe FA, et al: Anosmin-1 contributes to brain tumor malignancy through integrin signal pathways. Endocr Relat Cancer. 21:85–99. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kang YK, Hong SW, Lee H and Kim WH: Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog. 49:798–804. 2010.PubMed/NCBI | |
|
Wang F, Feng Y, Li P, Wang K, Feng L, Liu YF, Huang H, Guo YB, Mao QS and Xue WJ: RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget. 7:4279–4297. 2016.PubMed/NCBI | |
|
Matsuzaki T, Hanai S, Kishi H, Liu Z, Bao Y, Kikuchi A, Tsuchida K and Sugino H: Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway. J Biol Chem. 277:19008–19018. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Adam MG, Berger C, Feldner A, Yang WJ, Wüstehube-Lausch J, Herberich SE, Pinder M, Gesierich S, Hammes HP, Augustin HG, et al: Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis. Circ Res. 113:1206–1218. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Sullenger BA and Rich JN: Notch signaling in cancer stem cells. Adv Exp Med Biol. 727:174–185. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Brito GC, Fachel AA, Vettore AL, Vignal GM, Gimba ER, Campos FS, Barcinski MA, Verjovski-Almeida S and Reis EM: Identification of protein-coding and intronic noncoding RNAs down-regulated in clear cell renal carcinoma. Mol Carcinog. 47:757–767. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, Sugimoto H, Takeda S and Nakao A: Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol. 18:572–579. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI | |
|
Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S and Nakao A: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 289:170–177. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi M, Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S and Kodera Y: Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol. 105:381–386. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Okamura Y, Nomoto S, Hayashi M, Hishida M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y, et al: Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Lett. 312:150–157. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, et al: Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol. 43:88–94. 2013.PubMed/NCBI | |
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, et al: Dynamin 3: A new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther. 6:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, et al: Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res. 32:652013. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi M, Nomoto S, Hishida M, Inokawa Y, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, et al: Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer. 14:1082014. View Article : Google Scholar : PubMed/NCBI | |
|
Hishida M, Inokawa Y, Takano N, Nishikawa Y, Iwata N, Kanda M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, et al: Protein tyrosine kinase 7: A hepatocellular carcinoma-related gene detected by triple-combination array. J Surg Res. 195:444–453. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Takano N, Hishida M, Inokawa Y, Hayashi M, Kanda M, Nishikawa Y, Iwata N, Kobayashi D, Tanaka C, Yamada S, et al: CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. Int J Oncol. 46:1963–1970. 2015.PubMed/NCBI | |
|
Higuchi T, Todaka H, Sugiyama Y, Ono M, Tamaki N, Hatano E, Takezaki Y, Hanazaki K, Miwa T, Lai S, et al: Suppression of microRNA-7 (miR-7) biogenesis by nuclear factor 90-nuclear factor 45 complex (NF90-NF45) controls cell proliferation in hepatocellular carcinoma. J Biol Chem. 291:21074–21084. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
You Y, Tan JX, Dai HS, Chen HW, Xu XJ, Yang AG, Zhang YJ, Bai LH and Bie P: MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma. Oncotarget. 7:57099–57116. 2016.PubMed/NCBI | |
|
Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu D, Zhang Y, Li Y, Gu Q, Dong X, et al: Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma. Oncotarget. 7:24383–24401. 2016.PubMed/NCBI | |
|
Liu Z, Wang J, Mao Y, Zou B and Fan X: MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells. Oncol Lett. 11:433–438. 2016.PubMed/NCBI | |
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ: miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Huan L, Bao C, Chen D, Li Y, Lian J, Ding J, Huang S, Liang L and He X: MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-κB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci. 107:258–266. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, Jiang H, Liu Y, Huang Y, Xiong X, Wu H and Dai X: MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res. 343:135–147. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng YB, Liang XH, Zhang GX, Jiang N, Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI | |
|
Sakabe T, Azumi J, Umekita Y, Toriguchi K, Hatano E, Hirooka Y and Shiota G: Prognostic relevance of miR-137 in patients with hepatocellular carcinoma. Liver Int. 37:271–279. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu M, Lin Y, Zhou Y, Jin H, Hou B, Wu Z, Li Z, Jian Z and Sun J: MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4. Onco Targets Ther. 9:4705–4714. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tang B, Lei B, Qi G, Liang X, Tang F, Yuan S, Wang Z, Yu S and He S: MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res. 35:932016. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan T, He X, Yu J and Hang Z: MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma. Oncol Lett. 11:2941–2945. 2016.PubMed/NCBI | |
|
Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, Wang Q, Zhao F, Li J, Yao M, et al: miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget. 7:2672–2683. 2016.PubMed/NCBI | |
|
Deng B, Qu L, Li J, Fang J, Yang S, Cao Z, Mei Z and Sun X: MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma. Sci Rep. 6:266792016. View Article : Google Scholar : PubMed/NCBI | |
|
Yu G, Wang J, Xu K and Dong J: Dynamic regulation of uncoupling protein 2 expression by microRNA-214 in hepatocellular carcinoma. Biosci Rep. 36:362016. View Article : Google Scholar | |
|
Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T, et al: Circulating microRNA profiles in plasma: Identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget. 7:53820–53836. 2016.PubMed/NCBI | |
|
Meng X, Lu P and Fan Q: miR-367 promotes proliferation and invasion of hepatocellular carcinoma cells by negatively regulating PTEN. Biochem Biophys Res Commun. 470:187–191. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JS, Li HS, Huang JQ, Dong SH, Huang ZJ, Yi W, Zhan GF, Feng JT, Sun JC and Huang XH: MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Lett. 375:73–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia B and Liu Y: miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res. 8:2609–2619. 2016.PubMed/NCBI | |
|
Zhang L, Yu Z, Xian Y and Lin X: microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma. FEBS Open Bio. 6:155–164. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H, Yu M, Lin Y, Hou B, Wu Z, Li Z and Sun J: MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET. Onco Targets The. 9:3281–3289. 2016. | |
|
Xiao Y, Tian Q, He J, Huang M, Yang C and Gong L: MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor. Onco Targets Ther. 9:3535–3544. 2016.PubMed/NCBI | |
|
Tu K, Liu Z, Yao B, Han S and Yang W: MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974. 2016.PubMed/NCBI | |
|
Wang W, Zhang H, Wang L, Zhang S and Tang M: miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res Commun. 473:987–992. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y, Xie H, Zhou L, Zheng S and Wang W: MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. Cancer Sci. 107:424–432. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong S, Chen W, Yang J and Li H: MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway. Sci Rep. 6:223282016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang C, Li J and Zhuang SM: Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. Mutat Res. 638:205–209. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L, Han S, Yuan Q and Yang M: MiRNA-192 [corrected] and miRNA-204 directly suppress lncRNA HOTTIP and interrupt GLS1-mediated glutaminolysis in hepatocellular carcinoma. PLoS Genet. 11:e10057262015. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y and Gu X: MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One. 7:e297502012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YF, Yang CC, Kao SY, Liu CJ, Lin SC and Chang KW: MicroRNA-211 enhances the oncogenicity of carcinogen-induced oral carcinoma by repressing TCF12 and increasing antioxidant activity. Cancer Res. 76:4872–4886. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Lee S, Bae H, Kang HS and Kim SJ: Genome-wide identification of target genes for miR-204 and miR-211 identifies their proliferation stimulatory role in breast cancer cells. Sci Rep. 6:252872016. View Article : Google Scholar : PubMed/NCBI | |
|
Ye L, Wang H and Liu B: miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Asuthkar S, Velpula KK, Chetty C, Gorantla B and Rao JS: Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 3:1439–1454. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, et al: Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 40:841–849. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xia B, Yang S, Liu T and Lou G: miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015. View Article : Google Scholar : PubMed/NCBI | |
|
Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hong L, Ya-Wei L, Hai W, Qiang Z, Jun-Jie L, Huang A, Song-Tao Q and Yun-Tao L: MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway. J Neurooncol. 128:35–45. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shao J, Cao J, Liu Y, Mei H, Zhang Y and Xu W: MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2. FEBS Open Bio. 5:893–899. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ge YZ, Xu LW, Xu Z, Wu R, Xin H, Zhu M, Lu TZ, Geng LG, Liu H, Zhou CC, et al: Expression profiles and clinical significance of microRNAs in papillary renal cell carcinoma: A STROBE-compliant observational study. Medicine. 94:e7672015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Zhu HQ, Ma CQ, Li HG, Liu FF, Chang H and Lu J: MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression. Biomed Pharmacother. 79:315–320. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC and Sung JL: Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology. 96:527–529. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L, et al: Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 16:413–422. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H and Mori M: Specific gene-expression profiles of non-cancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 13:947–954. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T and Mori M: Molecular signatures of non-cancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 45:146–152. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Utsunomiya T, Ishikawa D, Asanoma M, Yamada S, Iwahashi S, Kanamoto M, Arakawa Y, Ikemoto T, Morine Y, Imura S, et al: Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma. Hepatol Res. 44:631–638. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Utsunomiya T, Shimada M, Morine Y, Tajima A and Imoto I: Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci. 105:749–754. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Meckelein B, de Silva HA, Roses AD, Rao PN, Pettenati MJ, Xu PT, Hodge R, Glucksman MJ and Abraham CR: Human endopeptidase (THOP1) is localized on chromosome 19 within the linkage region for the late-onset Alzheimer disease AD2 locus. Genomics. 31:246–249. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Qi L, Li SH, Si LB, Lu M and Tian H: Expression of THOP1 and its relationship to prognosis in non-small cell lung cancer. PLoS One. 9:e1066652014. View Article : Google Scholar : PubMed/NCBI | |
|
Nomoto S, Hishida M, Inokawa Y, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and Kodera Y: Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis. Ann Surg Oncol. 21:(Suppl 3). S443–S450. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cressman DE, Diamond RH and Taub R: Rapid activation of the Stat3 transcription complex in liver regeneration. Hepatology. 21:1443–1449. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sonohara F, Nomoto S, Inokawa Y, Hishida M, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H, et al: High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncol Rep. 33:767–773. 2015.PubMed/NCBI |
